Connection

GEORGE CHOLANKERIL to Antiviral Agents

This is a "connection" page, showing publications GEORGE CHOLANKERIL has written about Antiviral Agents.
Connection Strength

2.502
  1. Recent advances in liver transplantation with HCV seropositive donors. F1000Res. 2019; 8.
    View in: PubMed
    Score: 0.412
  2. Direct-Acting Antiviral Therapy and Improvement in Graft Survival of Hepatitis C Liver Transplant Recipients. Transplantation. 2017 12; 101(12):e349.
    View in: PubMed
    Score: 0.356
  3. Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents. Clin Gastroenterol Hepatol. 2018 03; 16(3):452-453.
    View in: PubMed
    Score: 0.350
  4. Rates of liver retransplantation in the United States are declining in the era of direct-acting antiviral agents. J Viral Hepat. 2017 12; 24(12):1194-1195.
    View in: PubMed
    Score: 0.349
  5. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. Clin Infect Dis. 2023 02 18; 76(4):592-599.
    View in: PubMed
    Score: 0.128
  6. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era. Clin Gastroenterol Hepatol. 2023 08; 21(9):2288-2297.e4.
    View in: PubMed
    Score: 0.126
  7. Comparable Survival for Hepatitis C-Related Hepatocellular Carcinoma After Liver Transplantation Irrespective of Viremic Status. Clin Gastroenterol Hepatol. 2023 05; 21(5):1362-1364.e1.
    View in: PubMed
    Score: 0.120
  8. Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients. Hepatology. 2018 08; 68(2):792-793.
    View in: PubMed
    Score: 0.093
  9. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol. 2018 Jan 21; 24(3):315-322.
    View in: PubMed
    Score: 0.090
  10. Optimal timing for hepatitis C antiviral therapy in the peritransplant period? Hepatology. 2017 09; 66(3):1004.
    View in: PubMed
    Score: 0.087
  11. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. Hepatology. 2017 07; 66(1):46-56.
    View in: PubMed
    Score: 0.086
  12. The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C. Telemed J E Health. 2017 10; 23(10):870-873.
    View in: PubMed
    Score: 0.085
  13. Indications for antiviral therapy for chronic hepatitis B in pregnant mothers. BMJ Case Rep. 2016 Nov 15; 2016.
    View in: PubMed
    Score: 0.083
  14. Changing trends in aetiology-based hospitalizations with end-stage liver disease in the United States from 2016 to 2019. Liver Int. 2022 11; 42(11):2390-2395.
    View in: PubMed
    Score: 0.031
  15. Trends in the Prevalence of Hepatitis C Virus Infection based on the Insurance Status in the United States from 2013 to 2018. Liver Int. 2022 02; 42(2):340-349.
    View in: PubMed
    Score: 0.029
  16. Trends in mortality in hepatitis C infection and alcoholic liver disease based on drug overdose in the United States. J Viral Hepat. 2021 02; 28(2):436-439.
    View in: PubMed
    Score: 0.027
  17. Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017. Gastroenterology. 2019 10; 157(4):1055-1066.e11.
    View in: PubMed
    Score: 0.025
  18. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology. 2018 10; 155(4):1154-1163.e3.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.